http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Article/list/43793 Latest news on glaucoma therapies, surgical techniques and instruments, imaging, diagnostics, non-penetrating surgery, implants and shunts, controversies and complications, patient and practice management. 2013-05-24T20:12:44Z http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Axial-length-affects-RNFL-thickness-profiles/ArticleStandard/Article/detail/796675?contextCategoryId=43793&ref=25 Axial length/refractive status affects the peripapillary retinal nerve fibre layer (RNFL) thickness profile in eyes measured by RTVue OCT. 2012-11-21T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462012/796675null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/Rudin-Glaucoma-Prize-winner-announced/ArticleStandard/Article/detail/796674?contextCategoryId=43793&ref=25 Dr Daniel Stamer has been awarded the prestigious Lewis Rudin Glaucoma Prize 2012. 2012-11-20T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462012/796674null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/Anti-glaucoma-eye-drops-linked-to-meibomian-gland-/ArticleStandard/Article/detail/793155?contextCategoryId=43793&ref=25 The long-term use of anti-glaucoma eye drops is linked to changes in meibomian gland morphology and function. 2012-10-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422012/793155null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Legal-fitness-to-drive-influenced-by-BEMD/ArticleStandard/Article/detail/789394?contextCategoryId=43793&ref=25 Better eye mean deviation (BEMD) strongly affects a patient's legal fitness to drive (LFTD), according to recently published data. 2012-09-25T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382012/789394null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/ICS-use-maintains-RNFL-rate/ArticleStandard/Article/detail/786490?contextCategoryId=43793&ref=25 Intranasal corticosteroids (ICS) maintain retinal nerve fibre layer (RNFL) thickness and optic nerve cup to disc ratio among patients with glaucoma or glaucoma suspect. 2012-09-04T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/352012/786490null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Contact-lens-sensor-provides-24-hour-IOP-monitorin/ArticleStandard/Article/detail/786489?contextCategoryId=43793&ref=25 A contact lens sensor is able to provide continuous 24-hour IOP monitoring for the management of glaucoma. 2012-09-03T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/352012/786489null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/Statins-reduce-OAG-risk-in-hyperlipidemia/ArticleStandard/Article/detail/785212?contextCategoryId=43793&ref=25 The use of statins has been linked to a significant decrease in open-angle glaucoma (OAG) risk in patients with hyperlipidemia. 2012-08-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/332012/785212null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/Caffeine-increases-IOP-and-OPP-in-POAG/ArticleStandard/Article/detail/785208?contextCategoryId=43793&ref=25 Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients. 2012-08-20T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/332012/785208null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Glaucomatous-damage-detected-with-SD-OCT/ArticleStandard/Article/detail/784460?contextCategoryId=43793&ref=25 SD-OCT imaging and retinal nerve fibre layer (RNFL) assessment successfully detects pre-perimetric glaucomatous damage. 2012-08-15T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/322012/784460null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Anterior-chamber-factors-identified-for-OAG/ArticleStandard/Article/detail/782703?contextCategoryId=43793&ref=25 Anterior chamber depth (ACD) and anterior chamber angle (ACA) were the factors identified relating to the progression of open-angle glaucoma (OAG). 2012-08-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/302012/782703null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/IOP-lowered-with-trab-and-combination-trab/ArticleStandard/Article/detail/781940?contextCategoryId=43793&ref=25 IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma. 2012-07-26T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/292012/781940null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/In-the-thick-of-it-parameters-for-glaucoma-detecti/ArticleStandard/Article/detail/781036?contextCategoryId=43793&ref=25 Macular ganglion cell complex (mGCC) and peripapillary retinal nerve fiber layer (ppRNFL) thickness can be used as structural parameters for detecting preperimetric glaucoma. 2012-07-17T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/282012/781036null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/UK-charity-donates-generous-funding-for-eye-diseas/ArticleStandard/Article/detail/781144?contextCategoryId=43793&ref=25 Fight for Sight has donated £1.6 million towards ten research grants focused on tackling sight loss and eye disease treatment. 2012-07-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/282012/781144null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/VEGF-levels-in-Tenon-tissue-linked-to-glaucoma-sur/ArticleStandard/Article/detail/779357?contextCategoryId=43793&ref=25 Vascular endothelial growth factor (VEGF) levels in the Tenon tissue and final IOP is significantly correlated to 1-year surgical outcomes of glaucoma surgery in patients with primary open-angle glaucoma (POAG) 2012-07-05T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262012/779357null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/BRI-incidence-higher-in-MMC-augmented-trabeculecto/ArticleStandard/Article/detail/778426?contextCategoryId=43793&ref=25 Incidence of bleb-related infection (BRI) is higher in Mitomycin C (MMC) augmented trabeculectomy but is reduced to a lower level. 2012-06-28T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/252012/778426null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Modified-DRPT-better-for-detecting-primary-angle-c/ArticleStandard/Article/detail/764729?contextCategoryId=43793&ref=25 Conducting a modified dark room provocative test (DRPT) is better for the diagnosis of primary angle closure, compared to gonioscopic angle assessment. 2012-03-26T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112012/764729null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Safe-and-effective-barrier-against-contamination-d/ArticleStandard/Article/detail/726469?contextCategoryId=43793&ref=25 Using a sterile, disposable barrier for the G-probe transsceleral cyclophotocoagulation (TSCPC) device is a safe and effective method of preventing contamination in consecutive patients. 2011-06-14T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/242011/726469null HTML http://www.oteurope.com/ophthalmologytimeseurope/Featured+articles/Diverse-factors-affect-management/ArticleStandard/Article/detail/728670?contextCategoryId=43793&ref=25 Ever-widening knowledge base proves that there's more to it than controlling IOPs. 2011-06-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262011/728670null XML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma/Stability-a-strength-of-filtration-device/ArticleStandard/Article/detail/728671?contextCategoryId=43793&ref=25 Performance compares favourably with trabeculectomy, in physician's experience 2011-06-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262011/728671null XML http://www.oteurope.com/ophthalmologytimeseurope/Featured+articles/Trial-compares-glaucoma-implants/ArticleStandard/Article/detail/728662?contextCategoryId=43793&ref=25 Baerveldt device showed better outcomes but required more interventions then Ahmed valve. 2011-06-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262011/728662null XML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Glaucoma-innovation-for-end-of-2010/ArticleStandard/Article/detail/676036?contextCategoryId=43793&ref=25 The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010 2010-06-30T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262010/676036null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/World-Glaucoma-Day/ArticleStandard/Article/detail/660356?contextCategoryId=43793&ref=25 Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society. 2010-03-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112010/660356null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Innovative-glaucoma-research-award/ArticleStandard/Article/detail/655841?contextCategoryId=43793&ref=25 The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon. 2010-02-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/072010/655841null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-study-demonstrates-potential-for-improving-gla/ArticleStandard/Article/detail/651124?contextCategoryId=43793&ref=25 Research claims that imaging devices can effectively support ophthalmologists with glaucoma diagnosis 2010-01-13T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032010/651124null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Alcon-acquires-Optonol/ArticleStandard/Article/detail/648245?contextCategoryId=43793&ref=25 Alcon acquires Optinol and enters glaucoma surgical market. 2009-12-14T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512009/648245null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Scottish-Medicines-Consortium-accepts-first-preser/ArticleStandard/Article/detail/647247?contextCategoryId=43793&ref=25 The Scottish Medicines Consortium (SMC) has announced that Saflutan (tafluprost) has been accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension 2009-12-08T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/502009/647247null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Santen-CEO-joins-Glaucoma-Research-Foundation/ArticleStandard/Article/detail/640189?contextCategoryId=43793&ref=25 Adrienne Graves, CEO of Santen Inc., has been appointed to the Glaucoma Research Foundation?s board of directors. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640189null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-generation-of-diagnostic-ultrasound-system-unv/ArticleStandard/Article/detail/640187?contextCategoryId=43793&ref=25 Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640187null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Laser-system-for-treatment-of-glaucoma-gets-Europe/ArticleStandard/Article/detail/640188?contextCategoryId=43793&ref=25 The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval. 2009-11-11T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462009/640188null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-related-to-selenium-levels/ArticleStandard/Article/detail/622245?contextCategoryId=43793&ref=25 The pathology of glaucoma is likely to be related to the presence and levels of selenium, according to the results of a study published in the August issue of the British Journal of Ophthalmology. 2009-09-02T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/352009/622245null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Implant-with-potential-to-permanently-treat-glauco/ArticleStandard/Article/detail/619318?contextCategoryId=43793&ref=25 OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. 2009-08-19T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/342009/619318null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/NicOx-reacquires-rights-to-PF-03187207-for-glaucom/ArticleStandard/Article/detail/619344?contextCategoryId=43793&ref=25 NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data. 2009-08-19T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/342009/619344null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Alcon-discontinues-development-of-anecortave-aceta/ArticleStandard/Article/detail/615862?contextCategoryId=43793&ref=25 Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma. 2009-08-05T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/322009/615862null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/A-comparison-of-ELT-and-SLT/ArticleStandard/Article/detail/612228?contextCategoryId=43793&ref=25 A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma. 2009-07-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/302009/612228null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Pioneering-ophthalmologist-dies-aged-92/ArticleStandard/Article/detail/612233?contextCategoryId=43793&ref=25 Ronald Pitts Crick, the ophthalmologist who was behind the development of the operating microscope, has died aged 92. 2009-07-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/302009/612233null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Business-eyes-up-development-of-new-glaucoma-treat/ArticleStandard/Article/detail/610503?contextCategoryId=43793&ref=25 Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. The unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets. 2009-07-15T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/292009/610503null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-and-blocked-blood-vessels/ArticleStandard/Article/detail/608777?contextCategoryId=43793&ref=25 A study reported in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology correlates the incidence of silent cerebral infarcts (SCI) and visual field loss in patients with normal-tension glaucoma. 2009-07-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/282009/608777null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Alcon-discontinues-anecortave-acetate/ArticleStandard/Article/detail/608776?contextCategoryId=43793&ref=25 Alcon has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma. 2009-07-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/282009/608776null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Gene-therapies/ArticleStandard/Article/detail/605269?contextCategoryId=43793&ref=25 Ocular applications of gene therapies are increasing, as is our understanding of the molecular pathogenesis of glaucoma. 2009-06-24T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/262009/605269null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/IGA-urges-the-public-not-to-cut-back-on-eye-tests/ArticleStandard/Article/detail/600871?contextCategoryId=43793&ref=25 The International Glaucoma Association (IGA) is urging people not to cut back on eye tests due to the recession. 2009-06-03T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/232009/600871null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-data-on-compounds-for-the-treatment-of-glaucom/ArticleStandard/Article/detail/599408?contextCategoryId=43793&ref=25 During the recent ARVO congress, Sylentis provided an update on recent advances made by the company in the development a product for ocular pain associated with dry eye syndrome that addresses TRPV1 receptor, a nociceptor able to transmit stimuli. 2009-05-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/212009/599408null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/New-chairman-of-GRF/ArticleStandard/Article/detail/599414?contextCategoryId=43793&ref=25 Kuldev Singh, MD, Professor of ophthalmology, has been appointed chairman of the Glaucoma Research Foundation (GRF). 2009-05-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/212009/599414null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Catioprost-gets-the-go-ahead-for-Phase-III-trial/ArticleStandard/Article/detail/597504?contextCategoryId=43793&ref=25 Novagali Pharma, the French pharmaceutical ophthalmic company, is to conduct a Phase III clinical trial of Catioprost (Nova21027) its Investigational New Drug Application (IND). 2009-05-13T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/202009/597504null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Canaloplasty-2-year-clinical-results-published/ArticleStandard/Article/detail/597502?contextCategoryId=43793&ref=25 Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients. 2009-05-13T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/202009/597502null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Cautious-welcome-for-new-glaucoma-guidelines/ArticleStandard/Article/detail/595124?contextCategoryId=43793&ref=25 New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community. 2009-04-29T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/182009/595124null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Tafluprost-now-licensed-worldwide/ArticleStandard/Article/detail/594147?contextCategoryId=43793&ref=25 A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd. 2009-04-22T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/172009/594147null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/24-hour-IOP-monitoring/ArticleStandard/Article/detail/591774?contextCategoryId=43793&ref=25 A Swiss startup company, Sensimed, has developed a novel technology for measuring increases in intraocular pressure. 2009-04-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/152009/591774null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Latest-predictive-factor-for-glaucoma/ArticleStandard/Article/detail/589866?contextCategoryId=43793&ref=25 Quantitative analysis of colour vision defects provides the possibility of follow-up and may be a useful means for detecting early glaucomatous changes in patients with normal visual fields. 2009-04-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/142009/589866null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Glaucoma-link-to-different-gene-variations/ArticleStandard/Article/detail/589868?contextCategoryId=43793&ref=25 While researching the long-suspected gene linked to glaucoma, WDR36, Michael Walter, PhD, and team discovered that the gene STL1 is only one of many other genes in which mutations must take place in order for WDR36 to cause glaucoma. 2009-04-01T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/142009/589868null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Canaloplasty-adoption-website-launched/ArticleStandard/Article/detail/587344?contextCategoryId=43793&ref=25 iForum, a surgeon-support website to enable the adoption of canaloplasty into clinicians' practices, has been launched by iScience Interventional. 2009-03-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122009/587344null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Nutritional-supplement-market-growing/ArticleStandard/Article/detail/587354?contextCategoryId=43793&ref=25 The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan. 2009-03-18T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/122009/587354null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/BAK-free-latanoprost-safe-and-effective/ArticleStandard/Article/detail/585407?contextCategoryId=43793&ref=25 The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at the Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria. 2009-03-11T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/102009/585407null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Motion-Displacement-Test-on-show-for-World-Glaucom/ArticleStandard/Article/detail/585771?contextCategoryId=43793&ref=25 The Motion Displacement Test (MDT), developed by Moorfields Eye Hospital in partnership with UCL Institute of Ophthalmology and City University London will be on show during World Glaucoma Day (March 12th) to demonstrate some of the latest glaucoma diagnostic equipment. 2009-03-11T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112009/585771null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/World-Glaucoma-Day-around-Europe/ArticleStandard/Article/detail/585773?contextCategoryId=43793&ref=25 Public screenings will take place at a variety of venues including private practices and hospitals in Austria, Belgium, Bulgaria, Greece, Italy, Spain and Switzerland. 2009-03-11T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112009/585773null HTML http://www.oteurope.com/ophthalmologytimeseurope/Latest+News/Italian-campaign-to-abolish-red-tape-and-help-glau/ArticleStandard/Article/detail/585772?contextCategoryId=43793&ref=25 Dr Tiziana Fattori of Per Vedere Fatti Vedere onlus in Italy explains the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma. 2009-03-11T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/112009/585772null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Testing-for-glaucoma-through-the-eyelid/ArticleStandard/Article/detail/582699?contextCategoryId=43793&ref=25 The Diaton tonometer (BiCOM), a non-invasive and painless way to measure intraocular pressure (IOP) through the eyelid, has been showcased by Phycon Medical at the 2009 meeting of the Florida Osteopathic Medical Association (FOMA). 2009-02-25T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082009/582699null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Accuracy-of-IOP-measurements/ArticleStandard/Article/detail/581661?contextCategoryId=43793&ref=25 Dynamic contour tonometry (DCT) may be more accurate than Goldmann applanation tonometry (GAT) in measuring intraocular pressure (IOP), according to study results published in the February issue of Eye. 2009-02-18T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/082009/581661null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Carbon-monoxide-lowers-IOP/ArticleStandard/Article/detail/578722?contextCategoryId=43793&ref=25 CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology. 2009-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062009/578722null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/New-glaucoma-testing-device-praised/ArticleStandard/Article/detail/578731?contextCategoryId=43793&ref=25 The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods. 2009-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062009/578731null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Laser-reduces-IOP/ArticleStandard/Article/detail/578733?contextCategoryId=43793&ref=25 A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd. 2009-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062009/578733null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/OPKO-launches-new-imaging-device-and-kicks-off-tri/ArticleStandard/Article/detail/578723?contextCategoryId=43793&ref=25 OPKO Health, Inc has received FDA marketing clearance on an imaging device and launched clinical trials of a new glaucoma shunt, the company has announced. 2009-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062009/578723null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Researchers-awarded-prize-for-stem-cell-research/ArticleStandard/Article/detail/578732?contextCategoryId=43793&ref=25 The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases. 2009-02-04T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/062009/578732null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Home-glaucoma-test-patented/ArticleStandard/Article/detail/577233?contextCategoryId=43793&ref=25 GlaucomaCheck, an online visual field test allowing for clinical grade at-home glaucoma screening, has been launched by VisionRx. 2009-01-28T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042009/577233null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Patient-compliance-and-text-messaging/ArticleStandard/Article/detail/576018?contextCategoryId=43793&ref=25 A clinical trial assessing glaucoma treatment compliance of patients using text and telephone messaging technology has been launched by the Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, US. 2009-01-21T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/042009/576018null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Controlling-IOP-with-SLT-and-latanoprost/ArticleStandard/Article/detail/574826?contextCategoryId=43793&ref=25 Both selective laser trabeculoplasty (SLT) and latanoprost are effective at controlling the level and fluctuation of intraocular pressure (IOP), according to a study published online ahead of print by the British Journal of Ophthalmology. 2009-01-14T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032009/574826null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Treating-paediatric-glaucoma/ArticleStandard/Article/detail/574869?contextCategoryId=43793&ref=25 Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology. 2009-01-14T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/032009/574869null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Calculating-risk-in-glaucoma/ArticleStandard/Article/detail/573914?contextCategoryId=43793&ref=25 Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology. 2009-01-08T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/022009/573914null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/The-improvement-in-glaucoma-monitoring-devices/ArticleStandard/Article/detail/571657?contextCategoryId=43793&ref=25 New imaging techniques are allowing more objective quantification of glaucoma diagnosis and progression, according to study results published online ahead of print by the British Journal of Ophthalmology. 2008-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512008/571657null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Latisse-recommended-for-eyelash-enhancement/ArticleStandard/Article/detail/571654?contextCategoryId=43793&ref=25 Latisse (bimatoprost solution 0.03%) (Allergan, Inc) has been recommended for FDA approval as a treatment for hypertrichosis of the eyelashes. 2008-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512008/571654null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Ginkgo-supplement-suppresses-steroid-induced-ocula/ArticleStandard/Article/detail/571660?contextCategoryId=43793&ref=25 Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology. 2008-12-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/512008/571660null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/The-impact-of-religion-on-medication-compliance/ArticleStandard/Article/detail/570076?contextCategoryId=43793&ref=25 Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO). 2008-12-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/492008/570076null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Azarga-approved-by-EMEA/ArticleStandard/Article/detail/569988?contextCategoryId=43793&ref=25 Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer. 2008-12-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/492008/569988null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-awareness-raising-strategies/ArticleStandard/Article/detail/568594?contextCategoryId=43793&ref=25 A multimedia campaign may be the best way to raise glaucoma awareness in the UK, according to study results published in the December issue of the British Journal of Ophthalmology. 2008-12-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/568594null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Best-tools-for-measuring-IOP-in-KC-patients/ArticleStandard/Article/detail/568593?contextCategoryId=43793&ref=25 The Pascal dynamic contour tonometer (DCT) and Reichert ocular response analyser (ORA) are the best tools for measuring corneal-compensated intraocular pressure (IOPcc) in patients with keratoconus (KC), according to study results published in the British Journal of Ophthalmology, December. 2008-12-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/568593null HTML http://www.oteurope.com/ophthalmologytimeseurope/Cataract+News/Anaesthesia-application-modes-compared/ArticleStandard/Article/detail/567588?contextCategoryId=43793&ref=25 Contact anaesthesia is just as safe and effective as peribulbar application for combined cataract and glaucoma surgery, according to study results published online ahead of print by Ophthalmologica. 2008-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/472008/567588null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-research-focuses-on-neurodegeneration/ArticleStandard/Article/detail/567878?contextCategoryId=43793&ref=25 The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US. 2008-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/482008/567878null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Software-innovations-from-Topcon/ArticleStandard/Article/detail/567602?contextCategoryId=43793&ref=25 Topcon Medical Systems has introduced new OCT mapping software and enhanced its image management system. 2008-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/472008/567602null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-management-varies-widely-in-the-UK/ArticleStandard/Article/detail/567608?contextCategoryId=43793&ref=25 The methods used to manage glaucoma vary widely across the United Kingdom, according to study results published in the November issue of Eye. 2008-11-26T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/472008/567608null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Shunt-reimbursement-amended/ArticleStandard/Article/detail/565168?contextCategoryId=43793&ref=25 The level of reimbursement of Optonol's Ex-PRESS Mini Glaucoma Shunt has been increased by the US Centers for Medicare and Medicaid (CMS), according to an announcement made by Optonol at the Glaucoma Subspecialty Day of this year's meeting of the American Academy of Ophthalmology. 2008-11-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/462008/565168null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/SLT-not-best-for-PEXG-patients/ArticleStandard/Article/detail/564350?contextCategoryId=43793&ref=25 Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology. 2008-11-17T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452008/564350null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Filtration-surgery-rates-drop/ArticleStandard/Article/detail/563720?contextCategoryId=43793&ref=25 The introduction of anti-glaucoma medications has reduced the need for filtration surgery, according to study results published online ahead of print by Eye. 2008-11-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452008/563720null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Punctal-plug-performs-well-at-Phase-II/ArticleStandard/Article/detail/564349?contextCategoryId=43793&ref=25 The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc. 2008-11-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452008/564349null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Zeiss-takes-over-partners-products/ArticleStandard/Article/detail/564351?contextCategoryId=43793&ref=25 Following the conclusion of the five-year extension of their agreement, Carl Zeiss Meditech has acquired all manufacturing assets from Welch Allyn of their glaucoma diagnostic products, including the Humphrey FDT Visual Field Instrument. 2008-11-10T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/452008/564351null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Surgery-increases-risk-of-conjunctival-scars/ArticleStandard/Article/detail/561865?contextCategoryId=43793&ref=25 A greater number of mast cells are present in the conjunctiva of glaucoma patients who have undergone ocular surgery, possibly leading to increased scarring, according to study results published online ahead of print by Eye. 2008-11-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/442008/561865null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-therapy-mode-of-actions-compared/ArticleStandard/Article/detail/561745?contextCategoryId=43793&ref=25 Although both latanoprost and timolol-dorzolamide fixed combination (TDFC) decrease 24-hour intraocular pressure (IOP) and enhance diastolic ocular perfusion pressure (DOPP) in primary open-angle glaucoma (POAG) patients, their mechanisms of action are different, according to study results published online by Investigative Ophthalmology and Visual Science. 2008-11-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/442008/561745null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Generic-Cosopt-and-Trusopt-available-now/ArticleStandard/Article/detail/561839?contextCategoryId=43793&ref=25 Generic versions of dorzolamide-timolol (Cosopt) and dorzolamide hydrochloride (Trusopt; Merck) are now available from Prasco. 2008-11-03T05:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/442008/561839null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Combigan-more-cost-effective-than-Cosopt/ArticleStandard/Article/detail/560700?contextCategoryId=43793&ref=25 The fixed combination of brimonidine/timolol is more cost effective than dorzolamide/timolol, according to a study published in the September/October issue of the European Journal of Ophthalmology. 2008-10-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/560700null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Thyroid-link-to-glaucoma/ArticleStandard/Article/detail/560487?contextCategoryId=43793&ref=25 Those suffering from thyroid disorders may also be at increased risk of glaucoma, according to study results published online ahead of print by the British Journal of Ophthalmology. 2008-10-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/560487null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Glaucoma-ignorance-highlighted/ArticleStandard/Article/detail/560729?contextCategoryId=43793&ref=25 On World Sight Day, Windows to Health, the Pfizer UK initiative to promote regular eye test attendance, unveiled results of the All Eyes on Glaucoma survey, which highlighted the UK's ignorance around glaucoma and its prevention. 2008-10-27T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/432008/560729null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/ZeissOptovue-dispute-resolved/ArticleStandard/Article/detail/558867?contextCategoryId=43793&ref=25 The intellectual property dispute between Carl Zeiss Meditec and Optovue has been resolved by the companies, ahead of the legal case reaching court. 2008-10-20T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422008/558867null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Novel-glaucoma-solution-enters-trials/ArticleStandard/Article/detail/558846?contextCategoryId=43793&ref=25 INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc. 2008-10-20T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/422008/558846null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Azarga-receives-positive-CHMP-opinion/ArticleStandard/Article/detail/557144?contextCategoryId=43793&ref=25 Azarga (brinzolamide 1%/timolol 0.5% ophthalmic suspension; Alcon Laboratories) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommends Azarga be granted marketing authorization from the European Medicines Agency (EMEA). 2008-10-13T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/412008/557144null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/New-Reichert-tonometer-launched/ArticleStandard/Article/detail/557239?contextCategoryId=43793&ref=25 The Reichert 7, a seventh-generation non-contact tonometer (NCT) with integrated one-touch measurement system, has been launched by Reichert Inc. 2008-10-13T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/412008/557239null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/MMC-boost-for-trabeculectomy/ArticleStandard/Article/detail/555567?contextCategoryId=43793&ref=25 Perioperative use of mitomycin-C (MMC) improves the long-term outcomes of trabeculectomy as a treatment for primary open-angle glaucoma (POAG), according to a study published online ahead of print by the British Journal of Ophthalmology. 2008-10-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/402008/555567null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Surgical-failure-risk-factors/ArticleStandard/Article/detail/555566?contextCategoryId=43793&ref=25 There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma. 2008-10-06T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/402008/555566null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Body-mass-influences-IOP/ArticleStandard/Article/detail/552566?contextCategoryId=43793&ref=25 The body mass index (BMI) of a patient may affect the results of a water-drinking test (WDT), according to study results published in October issue of the Journal of Ocular Pharmacology and Therapeutics. 2008-09-29T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/392008/552566null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Comparing-GAT-with-DCT/ArticleStandard/Article/detail/552560?contextCategoryId=43793&ref=25 Goldmann applanation tonometry (GAT) and dynamic contour tonometry (DCT) do not produce identical results when measuring intraocular pressure (IOP), according to study results published in the September 2008 issue of the Journal of Glaucoma. 2008-09-29T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/392008/552560null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/New-beta-blocker-trialled/ArticleStandard/Article/detail/551541?contextCategoryId=43793&ref=25 Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy. 2008-09-23T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382008/551541null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/TLT-laser-receives-FDA-clearance/ArticleStandard/Article/detail/551542?contextCategoryId=43793&ref=25 SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced. 2008-09-23T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/382008/551542null HTML http://www.oteurope.com/ophthalmologytimeseurope/Glaucoma+news/Canaloplasty-microcatheter-receives-clearance/ArticleStandard/Article/detail/547688?contextCategoryId=43793&ref=25 iScience Interventional has been granted 510k clearance from the FDA for its canaloplasty microcatheter for the catheterization and viscodilation of the Schlemm's canal in adult patients with primary open-angle glaucoma (POAG). 2008-09-08T04:00:00Z http://www.oteurope.com/ophthalmologytimeseurope/data/articlestandard/ophthalmologytimeseurope/362008/547688null HTML